Posted by Michael Wonder on 21 Jun 2017
Transparency Commission publishes opinion for Keytruda
20 June 2017 - The opinion relates to the use of pembrolizumab for the first-line use in patients with non-small-cell lung cancer.
The Commission considers the clinical service provided by pembrolizumab is important for use as first-line monotherapy treatment of patients with metastatic non-small cell lung cancer whose tumours express PD -L1 with a tumour proportion score = 50%, without tumour mutations of EGFR or ALK.
Pembrolizumab brings a moderate improvement in medical benefit (ASMR III) compared to the combination of platinum salts.
